Proteomic research in sarcomas – current status and future opportunities

Burns, Jessica; Wilding, Christopher P; Jones, Robin L.; Huang, Paul H.

doi:10.1016/j.semcancer.2019.11.003

Cited by 58 publications

(60 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining existing sarcoma nomograms with transcriptomic signatures may further improve accuracy of risk assessment 79 . Additionally, integration of gene expression analysis with other Omic profiling methodologies, such as proteomics and DNA methylation analysis, is also likely to improve prognostication with new biomarker-directed treatment opportunities [80][81][82][83] .…”

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

et al. 2021

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised disease. Prognostication in clinical practice relies predominantly on histological grading systems as well as sarcoma nomograms. Rapid developments in gene expression profiling technologies presented opportunities for applications in sarcoma. Molecular profiling of sarcomas has improved our understanding of the cancer biology of these rare cancers and identified potential novel therapeutic targets. In particular, transcriptomic signatures could play a role in risk classification in sarcoma to aid prognostication. Unlike other solid and haematological malignancies, transcriptomic signatures have not yet reached routine clinical use in sarcomas. Herein, we evaluate early developments in gene expression profiling in sarcomas that laid the foundations for transcriptomic signature development. We discuss the development and clinical evaluation of key transcriptomic biomarker signatures in sarcomas, including Complexity INdex in SARComas (CINSARC), Genomic Grade Index, and hypoxia-associated signatures. Prospective validation of these transcriptomic signatures is required, and prospective trials are in progress to evaluate reliability for clinical application. We anticipate that integration of these gene expression signatures alongside existing prognosticators and other Omics methodologies, including proteomics and DNA methylation analysis, could improve the identification of ‘high-risk’ patients who would benefit from more aggressive or selective treatment strategies. Moving forward, the incorporation of these transcriptomic prognostication signatures in clinical practice will undoubtedly advance precision medicine in the routine clinical management of sarcoma patients.

show abstract

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…With the limited response to current chemotherapy in LMS, there is a need for sustained efforts to define effective targeted therapies in LMS, which may include ATR inhibitors, PARP inhibitors and other DNA damage repair targets, PI3K/mTOR inhibitors [ 78 ], metabolic vulnerabilities such as exploiting arginine starvation [ 79 , 80 ] and directed immunotherapy. Furthermore, as omic technologies become more accessible and cost-effective, there should be concerted investigations to determine whether integration of multiomic measurements such as epigenomics, proteomics and metabolomics may yield more robust drug discovery targets and biomarkers [ 81 ]. Finally, given the rarity of the disease, there is an urgent need for international collaborations within a coordinated research strategy framework that minimizes overlap and maximizes the limited funding available in the field.…”

Section: Unmet Medical Needs Therapeutic Gaps and Future Perspectmentioning

confidence: 99%

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Kasper

Achee²,

Schuster³

et al. 2021

Cancers

View full text Add to dashboard Cite

As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.

show abstract

“…Kondo and Kawai suggested investigating (for STS) numerous potentially useful molecular proteomic markers which have contributed to cancer therapy, but they did not follow up on their suggestions [119]. However, in 2019 Burns et al stated that no proteomic markers for STS had reached the clinic [120]. Kane et al examined specimens from 60 STS patients, but pretreatment samples were available for only 23 and matched samples pre-and post-treatment for 12 [121].…”

Section: Biomarkersmentioning

confidence: 99%

Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Spałek

Kozak

Czarnecka

et al. 2020

Cancers

View full text Add to dashboard Cite

Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks. Finally, we summarize current recommendations of the STS neoadjuvant therapy response assessment.

show abstract

Proteomic research in sarcomas – current status and future opportunities

Cited by 58 publications

References 135 publications

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Contact Info

Product

Resources

About